PolarityTE — Investor Presentation (August 2019)
40 slides from PolarityTE's investor presentation, Aug 20, 2019
Slide 1: PolarityTE: Where Self Regenerates Self
Polarity TE" Where Self Regenerates Self” PolarityTE, Inc. Nasdaq: PTE
Slide 2: PolarityTE
PolarityTE" Where Self Regenerates Sel/* A biotechnology company focused on transforming the lives of patients.
Slide 3: Forward-Looking Statement
& Forward-Looking Statement This presentation contains forward-looking statements and projections. PolarityTE, Inc, (the "Company") makes no express or implied representation or warrant as to the completeness of this information or, in the case of projections, as to their attainability or the accura
Slide 4: About PolarityTE, Inc.
About PolarityTE, Inc. + Weare a tissue focused biotechnology company that uses a patient's own cells to generate new tissue. * State of the art research facility to develop products based on our platform technology * Centralized manufacturing facility based in Salt Lake City, Utah with plans to bui
Slide 5: Company History
Company History PolarityTE” 0 . — > SteolE @ Company formed Ski alle OsteoTE registered with FDA First patent m . application filed SkinTE registered with FDA 2015 ° 2016 2017 ‘39 2018 ° 2019 fe] Formosa fire Lab established at Research Park First patient treated PolarityTE” with SkinTE PolarityTE C
Slide 6: SkinTE Technology
SkinTE Technology PolarityTE manufactures products that take advantage of innate cellular micro-aggregates which contain progenitor cells that maintain the ability to regenerate structural tissues
Slide 7: Product Pipeline
Product Pipeline “kn Pl Enrollmer Int Initiated Lh Enrollment Recor Completed (ONT N PolarityTE” Where Sef eget of
Slide 8: Scientific Recognition
Scientific Recognition * Peer Reviewed Publication in International Wound Journal + Peer Reviewed Publication in Plastic Surgery Case Studies in press + 44 abstracts accepted for presentation at healthcare, scientific and clinical conferences around the world* - 20 abstracts accepted for podium pres
Slide 9: SkinTE: Fully Functional, Full-Thickness Skin Product
SkinTE: Fully Functional, Full-Thickness Skin Product Real Skin Matters Skin is much more than a single layer of cells providing a epidermal barrier—skin is the largest organ of the human body and requires regeneration of all components for normal function. * Sensation + Immunity * Sweating * Sebum
Slide 10: Current Treatment Options
Current Treatment Options Scaffolds & Matrices—No Cells + Lack living cells + Limited ability to regenerate tissue + Typically require secondary coverage with skin grafts Allogeneic/Xenogeneic Cells & Tissues * — Risk of immune system rejection of foreign cells and tissue + Can tesultin scarring + F
Slide 11: Split-Thickness Skin Graft Donor Sites
Split-Thickness Skin Graft Donor Sites Split-Thickness Skin Graft Harvesting Skin Graft Donor Site After 2 Years Following Harvest PolarityTE” ® PolarityTE 11 of 31
Slide 12: SkinTE
SkinTE SkinTE: * First and only FDA-registered product capable of regenerating functionally normal skin * Proven to regenerate full thickness skin with all layers (epidermis, dermis and hypodermis) and appendages (hair follicles and sebaceous glands) * SkinTE has produced function (sensation, sweat
Slide 13: SkinTE: FDA Registered Through HCT/P Pathway
SkinTE: FDA Registered Through 361 HCT/P Pathway + Minimally manipulated * Autologous - from the patient, for the patient * Homologous - skin for skin * Manufacture must not involve combination with another article, except for water, crystalloids or a sterilizing, preserving or storage agents * 361
Slide 14: SkinTE Was Designed to Reduce Barriers and Increase Availability
SkinTE Was Designed to Reduce Barriers and Increase Availability of Regenerative Treatments Broad Utilization: Surgeons Medical Doctors Podiatrists Physicians Assistants Nurses/Nurse Practitioners Ted Broad Applications To Date: + Acute wounds * Chronic wounds + Traumatic injuries * Acute burns * Bu
Slide 15: SkinTE Regenerates Functional Skin
SkinTE Regenerates Functional Skin SkinTE Applied to Chronic Wound on Right Lower Extremity (RLE) After Two Years of Failed Treatments Right Leg: Right Leg: Left Leg: Before SkinTE After SkinTE STSG Multi-Modality Imaging of Hair Follicles Confocal Confocal © E z= ao Merge Dual ESEM Stereoscopic 2 3
Slide 16: SkinTE Treats a Broad Spectrum of Wounds
SkinTE Treats a Broad Spectrum of Wounds Diabetic Foot Ulcer Venous Leg Ulcer Initial Wound ~7 weeks after single ~9 weeks after single Initial wound ~13 weeks after single application of SkinTE application of SkinTE application of SkinTE Chronic Wound Acute Wound Initial wound ~6 months after singl
Slide 17: SkinTE Treats a Broad Spectrum of Wounds
SkinTE Treats a Broad Spectrum of Wounds Pressure Sores - Sacral Ulcer Traumatic Injury - Lawnmower Accident iiiiaiwound ~9 weeks after single 24 weeks after single application of SkinTE application of SkinTE Traumatic Injury - Motor Vehicle Accident Initial wound ~20 weeks after single application
Slide 18: SkinTE Treats a Broad Spectrum of Wounds
SkinTE Treats a Broad Spectrum of Wounds Chronic Recurring Wound Burn Reconstruction — -s Initial wound ~11 weeks after single ~24 weeks after single Post-debridement ~13 months after single application of SkinTE application of SkinTE application of SkinTE Amputation Wound Post-Mohs Reconstruction P
Slide 19: Feedback from Patients, Providers and Thought-Leaders
Feedback from Patients, Providers and Thought-Leaders ». . oe we ‘ ~ F ; atasha, Burn Strvivorant i = PolarityTE™
Slide 20: Clinical Trials
Clinical Trials Patient Outcome from VLU Pilot Evaluation al Scientific Evidence Er Study description Study Primary endpoint | Enrollment Status Status/ Outcomes Multicenter, randomized controlled trial 102 patients Percentage of ulcers closed at Actively enrolling Interim analysis planned at evalua
Slide 21: SkinTE Successfully Closing DFUs & VLUs
SkinTE Successfully Closing DFUs & VLUs SkinTE Applied to a Diabetic Foot Ulcer SkinTE Applied to a Venous Leg Ulcer Pre-treatment ~8 weeks after a single application of SkinTE Pre-treatment ~7 weeks durability follow-up (Closed 22 days after single application of SkinTE) PolarityTE” ‘Where Sef Rege
Slide 22: Scientific Evidence
Scientific Evidence Diabetic Foot Ulcer (DFU) Pilot Trial Results presented at the Diabetic Limb Salvage Conference and the Symposium on Advanced Wound Care and The American Diabetes Association * 10 of 11 (90.9%) DFUs healed within 8 weeks of a single application of SkinTE + Mean time to healing wa
Slide 23: Defining the US Market
Defining the US Market Venous Leg Ulcers (VLUs) Diabetic Foot Ulcers (DFUs) Pressure Ulcers (PUs) Prevalence Prevalence 30.3mm 2.5mm Prevalence 600k ~670k ~200-360k ~1.0-2.5mm Estimated Number of Individuals to Prevalence of Venous Ulcers i ith Di in the United States Oo People in the U.S. With Diab
Slide 24: Defining the US Market
Defining the US Market Burns Wounds From Surgical Procedures Incidence Incidence 486k ~23mm ~230-680k Number of Cardiovascular, Digestive, Burn Injuries Receiving | ‘ i | " Urinary, Musculoskeletal, and Integumentary IMedieal Tratvenit (vig) In-Patient Surgeries Per Year | Yearly Hospitalizations ||
Slide 25: SkinTE Commercialization
SkinTE Commercialization & 2018 Limited Market Release 2019 Regional Market Release 2020 Full National Release * Chronic Wounds: Drive clinical evidence * Burn Wounds: Work with thought leaders and clinical advisors * Trauma Wounds: Increase market awareness PolarityTE” Where ef eget of" 25 of 31
Slide 26: Reimbursement
Reimbursement Hospital Inpatient: Outpatient Settings: Physician Office: * Bundled DRG payments * Bundled facility payments * Procedure and product payments Braiiye: ‘Where Sef Regenerates Sf” 26 of 31
Slide 27: OsteoTE Registered with the FDA in 2018
OsteoTE” Registered with the FDA in 2018 Load-Displacement Biomechanical Testing Craniomaxillofacial Spine Pre-Treatment Post OsteoTE
Slide 28: Financial Snapshot
Financial Snapshot * Cash, cash equivalents and short-term investments were $58.2 million as of June 30, 2019 f’ * Financing in April 2019 yielded ~$29 million of net proceeds * Inthe three months ended June 30, 2019, cash used in operations was approximately $4.1 million per month, 26% lower than c
Slide 29: Management Team
David Seaburg President of Corporate Development Cowen and Company Stephen Milner, MD, DDS, DSc, FACS Chief Clinical Officer Johns Hopkins Hospital & School of Medicine Jennifer Burdman, JD Chief Intellectual Property Officer & Deputy General Counsel king & Spalding LLP Matt Kemp Chief Commercial Of
Slide 30: Board of Directors
Board of Directors Peter Cohen, MBA Lead Director + Former Board Member of the NYSE + Former Chairman and CEO of Shearson Lehman Brothers + Former Chairman and CEO of Cowen Inc. + Vice Chairman and Lead Director of the Board of Directors of Scientific Games Corporation + Federal Reserve Internationa
Slide 31: Welcome to the Shift
& Welcome to the Shift PolarityTE® Corporate PolarityTE® Investors Relations www.PolarityTE.com Rich Haerle, MBA, MPH ParadigmShift@PolarityTE.com VP of Investor Relations Corporate Inquiries: (800) 378-2694 IR Inquiries: (385) 237-5786 Corporatelnquiries@PolarityTE.com IR@PolarityTE.com Nasdaq: PTE
Slide 32: Appendix
Appendix
Slide 33: Innovation: RTD and ARC Pipelines
Innovation: RTD and ARC Pipelines Related Technology Derivatives (RID) Programs Program Optimization & Development Prototype Modeling Clinical Development Market Commercialization Blo-Accelerant & Modulation ‘Composite Tissue System, ‘Advanced Cell/Tissue Devices ‘Advanced Parties ‘Advanced Fibers A
Slide 34: The Process: Standard of Care vs. SkinTE
The Process: Standard of Care vs. SkinTE sir Split-Thickness Skin Graft Healing Autologous Homologous Skin Construct Healing Current Standard of Care @ reerive
Slide 35: Where Skin Grafts Fail
Where Skin Grafts Fail SkinTE Following Replacement of Split-Thickness Skin Graft in Fibrotic Wound Bed Excision of skin graft 2 weeks post-op Post-Op ee" Conducting pinch test of SkinTE at 6 months Punch biopsy of SkinTE- regenerated skin depicts all layers of full-thickness skin and appendages Ret
Slide 36: Chronic Wound
Chronic Wound SkinTE Applied to Chronic Wound on Right Lower Extremity (RLE) After Two Years of Failed Treatments u a \ i 2-year-old chronic refractory wound on right lower extremity Right lower extremity 2-year-old previously ~12 weeks after single placed skin graft on left application of SkinTE lo
Slide 37: Patient Experience
Patient Experience “If |had to choose between SkinTE and another skin graft, | would choose SkinTE every time, because it is actually working, and you do not have a huge area of healthy skin removed that also then needs to heal, like with traditional skin grafts.” —Devon, a SkinTE Patient
Slide 38: Poster #CS-03
Poster #CS-03 Closure of refractory diabetic foot ulcers and venous stasis leg ulcers using a single application of an Receaviedieal autologous homologous skin construct in the clinic setting Center of US David G. Armstrong!?, Dennis Orgill’, Robert Galiano‘, Paul Glat®, Charles M. Zelen® 1 Southwes
Slide 39: Late Breaking: Results of a Pilot Evaluation of a Novel Autologous Homologous Skin Construct
Late Breaking: Results of a Pilot Evaluation of a Novel Autologous Homologous Skin Construct Treatment ; of Diabetic Foot Wounds Refractory to Conventional Treatments ba nstrong', Dennis O ber 4 Paul Introduction. Methods Conclusions References Results Case #05: DFU of ## Metatarsal of Left Foot (id
Slide 40: About SkinTE and Important Safety Information
PolarityTE” here Se Rogers Se” About SkinTE™ SkinTE is a human cellular and tissue-based product derived from a patient’s own skin (autologous) intended for the repair, reconstruction, and replacement of skin tissue. SkinTE is intended to be used by medical professionals for homologous uses of skin